Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of odanacatib for prevention of bone metastases in breast cancer
2008-002119-42Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer and bone metastases comparing odanacatib 5 mg once daily with placebo (2 arms). Primary endpoint: Time to first bone metastasis (first disease recurrence). Started Jul 2008; status: terminated.
02
Drugs
odanacatib
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on 2008-002119-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002119-42.